oxidopamine has been researched along with Wallerian Degeneration in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Wallerian Degeneration: Degeneration of distal aspects of a nerve axon following injury to the cell body or proximal portion of the axon. The process is characterized by fragmentation of the axon and its MYELIN SHEATH.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sajadi, A | 1 |
| Schneider, BL | 1 |
| Aebischer, P | 1 |
1 other study available for oxidopamine and Wallerian Degeneration
| Article | Year |
|---|---|
Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease.
Topics: Amphetamine; Animals; Cell Survival; Disease Models, Animal; Dopamine; Immunohistochemistry; Mice; M | 2004 |